Drugs / Influenza Vaccine, inactivated, quadrivlent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06208683 | Nov 2023 → Feb 2024 | influenza, mumps infectious disease | Sinovac Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Vaccine, inactivated, quadrivlent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208683 ↗ |
| Known as | QIV | “Biological: Influenza Vaccine, inactivated, quadrivlent(QIV)” NCT06208683 ↗ |
| Modality | Vaccine | “quadrivalent inactivated influenza vaccine” NCT06208683 ↗ |